Literature DB >> 22190897

RASopathies: Clinical Diagnosis in the First Year of Life.

M C Digilio1, F Lepri, A Baban, M L Dentici, P Versacci, R Capolino, R Ferese, A De Luca, M Tartaglia, B Marino, B Dallapiccola.   

Abstract

Diagnosis within Noonan syndrome and related disorders (RASopathies) still presents a challenge during the first months of life, since most clinical features used to differentiate these conditions become manifest later in childhood. Here, we retrospectively reviewed the clinical records referred to the first year of life of 57 subjects with molecularly confirmed diagnosis of RASopathy, to define the early clinical features characterizing these disorders and improve our knowledge on natural history. Mildly or markedly expressed facial features were invariably present. Congenital heart defects were the clinical issue leading to medical attention in patients with Noonan syndrome and LEOPARD syndrome. Feeding difficulties and developmental motor delay represented the most recurrent features occurring in subjects with cardiofaciocutaneous syndrome and Costello syndrome. Thin hair was prevalent among SHOC2 and BRAF mutation-positive infants. Café-au-lait spots were found in patients with LS and PTPN11 mutations, while keratosis pilaris was more common in individuals with SOS1, SHOC2 and BRAF mutations. In conclusion, some characteristics can be used as hints for suspecting a RASopathy during the first months of life, and individual RASopathies may be suspected by analysis of specific clinical signs. In the first year of life, these include congenital heart defects, severity of feeding difficulties and delay of developmental milestones, hair and skin anomalies, which may help to distinguish different entities, for their subsequent molecular confirmation and appropriate clinical management.

Entities:  

Year:  2011        PMID: 22190897      PMCID: PMC3214957          DOI: 10.1159/000331266

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  46 in total

1.  Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.

Authors:  A Sarkozy; E Conti; D Seripa; M C Digilio; N Grifone; C Tandoi; V M Fazio; V Di Ciommo; B Marino; A Pizzuti; B Dallapiccola
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

2.  Multiple lentigenes syndrome.

Authors:  R J Gorlin; R C Anderson; M Blaw
Journal:  Am J Dis Child       Date:  1969-06

3.  The face of Noonan syndrome: Does phenotype predict genotype.

Authors:  Judith E Allanson; Axel Bohring; Helmuth-Guenther Dörr; Andreas Dufke; Gabrielle Gillessen-Kaesbach; Denise Horn; Rainer König; Christian P Kratz; Kerstin Kutsche; Silke Pauli; Salmo Raskin; Anita Rauch; Anne Turner; Dagmar Wieczorek; Martin Zenker
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

4.  Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade.

Authors:  Laura Cesarini; Paolo Alfieri; Francesca Pantaleoni; Isabella Vasta; Marta Cerutti; Valentina Petrangeli; Paolo Mariotti; Chiara Leoni; Daniela Ricci; Stefano Vicari; Angelo Selicorni; Marco Tartaglia; Eugenio Mercuri; Giuseppe Zampino
Journal:  Am J Med Genet A       Date:  2009-02       Impact factor: 2.802

5.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

6.  Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

Authors:  Caroline Nava; Nadine Hanna; Caroline Michot; Sabrina Pereira; Nathalie Pouvreau; Tetsuya Niihori; Yoko Aoki; Yoichi Matsubara; Benoit Arveiler; Didier Lacombe; Eric Pasmant; Béatrice Parfait; Clarisse Baumann; Delphine Héron; Sabine Sigaudy; Annick Toutain; Marlène Rio; Alice Goldenberg; Bruno Leheup; Alain Verloes; Hélène Cavé
Journal:  J Med Genet       Date:  2007-08-17       Impact factor: 6.318

Review 7.  Costello syndrome: an overview.

Authors:  Raoul C M Hennekam
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-02-15       Impact factor: 3.908

8.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

9.  LEOPARD syndrome: clinical diagnosis in the first year of life.

Authors:  M Cristina Digilio; Anna Sarkozy; Andrea de Zorzi; Giuseppe Pacileo; Giuseppe Limongelli; Rita Mingarelli; Raffaele Calabrò; Bruno Marino; Bruno Dallapiccola
Journal:  Am J Med Genet A       Date:  2006-04-01       Impact factor: 2.802

Review 10.  Noonan syndrome.

Authors:  Ineke van der Burgt
Journal:  Orphanet J Rare Dis       Date:  2007-01-14       Impact factor: 4.123

View more
  25 in total

1.  Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes.

Authors:  Ana Justino; Patrícia Dias; Maria João Pina; Sónia Sousa; Luís Cirnes; Ana Berta Sousa; José Carlos Machado; José Luis Costa
Journal:  Eur J Hum Genet       Date:  2014-06-04       Impact factor: 4.246

2.  RASopathies: Presentation at the Genome, Interactome, and Phenome Levels.

Authors:  Urska Pevec; Neva Rozman; Blaz Gorsek; Tanja Kunej
Journal:  Mol Syndromol       Date:  2016-04-21

3.  Genotype and phenotype spectrum of NRAS germline variants.

Authors:  Franziska Altmüller; Christina Lissewski; Debora Bertola; Elisabetta Flex; Zornitza Stark; Stephanie Spranger; Gareth Baynam; Michelle Buscarilli; Sarah Dyack; Jane Gillis; Helger G Yntema; Francesca Pantaleoni; Rosa LE van Loon; Sara MacKay; Kym Mina; Ina Schanze; Tiong Yang Tan; Maie Walsh; Susan M White; Marena R Niewisch; Sixto García-Miñaúr; Diego Plaza; Mohammad Reza Ahmadian; Hélène Cavé; Marco Tartaglia; Martin Zenker
Journal:  Eur J Hum Genet       Date:  2017-05-03       Impact factor: 4.246

4.  Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.

Authors:  Andreas Hahn; Jessica Lauriol; Josef Thul; Kachina Behnke-Hall; Tushiha Logeswaran; Anne Schänzer; Nuray Böğürcü; Boyan K Garvalov; Martin Zenker; Bruce D Gelb; Susanne von Gerlach; Reinhard Kandolf; Maria I Kontaridis; Dietmar Schranz
Journal:  Am J Med Genet A       Date:  2015-02-23       Impact factor: 2.802

5.  Atrioventricular canal defect in patients with RASopathies.

Authors:  Maria Cristina Digilio; Francesca Romana Lepri; Maria Lisa Dentici; Alex Henderson; Anwar Baban; Maria Cristina Roberti; Rossella Capolino; Paolo Versacci; Cecilia Surace; Adriano Angioni; Marco Tartaglia; Bruno Marino; Bruno Dallapiccola
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

6.  Dysregulation of FHL1 spliceforms due to an indel mutation produces an Emery-Dreifuss muscular dystrophy plus phenotype.

Authors:  Heather R Tiffin; Zandra A Jenkins; Mary J Gray; Sophia R Cameron-Christie; Jennifer Eaton; Salim Aftimos; David Markie; Stephen P Robertson
Journal:  Neurogenetics       Date:  2013-03-02       Impact factor: 2.660

7.  Low-dose dasatinib rescues cardiac function in Noonan syndrome.

Authors:  Jae-Sung Yi; Yan Huang; Andrea T Kwaczala; Ivana Y Kuo; Barbara E Ehrlich; Stuart G Campbell; Frank J Giordano; Anton M Bennett
Journal:  JCI Insight       Date:  2016-12-08

8.  Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress.

Authors:  Elise Y Cai; Megan N Kufeld; Samantha Schuster; Sonali Arora; Madeline Larkin; Alexandre A Germanos; Andrew C Hsieh; Slobodan Beronja
Journal:  Cell Stem Cell       Date:  2020-06-08       Impact factor: 24.633

9.  Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.

Authors:  Michael Wey; Jungwoon Lee; Soon Seog Jeong; Jungho Kim; Jongyun Heo
Journal:  Biochemistry       Date:  2013-11-13       Impact factor: 3.162

10.  A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.

Authors:  Jonathan J Edwards; Simone Martinelli; Luca Pannone; Ivan Fai-Man Lo; Lisong Shi; Lisa Edelmann; Marco Tartaglia; Ho-Ming Luk; Bruce D Gelb
Journal:  Am J Med Genet A       Date:  2014-05-28       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.